Block listing Interim Review

LungLife AI, INC

15 May 2025

 

15 May 2025

LungLife AI, Inc.
(the "Company" or "LungLife")

Block Admission Six Monthly Return

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block admission pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

Name of Company:		LungLife AI, Inc.
Name of scheme:		1.    2010 Stock Incentive Plan 2.    2020 Stock Incentive Plan 3.    2021 Omnibus Long-Term Incentive Plan
Number and class of securities originally admitted:		1,356,139 common shares of US $0.0001 each
Date of admission:		15 November 2021
Period of return:	From:	15 November 2024	To:	15 May 2025
Balance of unallotted securities under scheme(s) from previous return:		1.    475,583 2.    201,374 3.    673,990
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1.    NIL 2.    NIL 3.    NIL
Less: Number of securities issued/allotted under scheme(s) during period:		1.    NIL 2.    NIL 3.    NIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period :		1.    475,583 2.    201,374 3.    673,990
Total number of securities in issue at the end of the period		30,658,603

Name of contact:	David Anderson, Chief Financial Officer
Telephone number of contact:	[phone]

For further information please contact:

LungLife AI, Inc.	www.lunglifeai.com
Paul Pagano, CEO	via [e-mail]
David Anderson, CFO
Allenby Capital Limited Nominated Adviser and Joint Broker Alex Brearley / Lauren Wright - Corporate Finance Matt Butlin / Guy McDougall - Equity Sales & Corporate Broking		Tel: [phone] [e-mail]
Goodbody (Joint Broker)	Tel: [phone]
Tom Nicholson / Cameron Duncan

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com.

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

 

END